PubRank

A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer (CheckMate040)

Clinical Trial ID NCT01658878

PubWeight™ 32.38‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01658878

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
2 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
3 Retracted The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int 2015 1.40
4 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
5 Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 2014 1.16
6 Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res 2013 1.00
7 Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013 0.99
8 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
9 Present and future therapies of hepatitis B: From discovery to cure. Hepatology 2015 0.96
10 Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015 0.93
11 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015 0.92
12 Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin 2015 0.92
13 Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol 2015 0.91
14 Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget 2016 0.88
15 Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol 2015 0.88
16 Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2016 0.88
17 Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol 2015 0.86
18 New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015 0.84
19 Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol 2015 0.84
20 PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Rep Oncol Med 2015 0.83
21 Immunotherapy for solid tumors--a review for surgeons. J Surg Res 2013 0.83
22 A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology 2016 0.82
23 Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol 2016 0.80
24 The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget 2016 0.79
25 Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol 2016 0.78
26 Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol 2016 0.78
27 Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer. Oncoimmunology 2014 0.77
28 Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015 0.77
29 Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015 0.77
30 Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol 2016 0.76
31 High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored? Oncoimmunology 2013 0.76
32 Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014 0.76
33 Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma 2016 0.75
34 Eradication Strategies for Chronic Hepatitis B Infection. Clin Infect Dis 2016 0.75
Next 100